Inactive Instrument

Press Releases Acceleron Pharma Inc.

Equities

XLRN

US00434H1086

Press Releases

Unlock all the news: Be the first to know and act before the market!

Acceleron Pharma : Completion of Acquisition or Disposition of Assets - Form 8-K	22/21/22	PU
ACCELERON PHARMA INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	22/21/22	AQ
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.	22/21/22	AQ
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer	18/21/18	BU
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer	10/21/10	BU
Acceleron Reports Third Quarter 2021 Financial Results - Form 8-K	05/21/05	PU
Acceleron: Q3 Earnings Snapshot	05/21/05	AQ
ACCELERON PHARMA INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	05/21/05	AQ
Acceleron Reports Third Quarter 2021 Financial Results	05/21/05	BU
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.	01/21/01	AQ
Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders	28/21/28	BU
ACCELERON PHARMA INC : Results of Operations and Financial Condition (form 8-K)	27/21/27	AQ
Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales	27/21/27	BU
ACCELERON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acceleron Pharma Inc. - XLRN	02/21/02	BU
Acceleron Pharma : Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma	01/21/01	BU
Acceleron Pharma : Merck spends $11.5B for Acceleron, possible blockbuster drug	30/21/30	AQ
Acceleron Pharma : REBLOZYL® (luspatercept-aamt) is a First-In-Class Erythroid Maturation Recombinant Fusion Protein Approved for the Treatment of Anemia in Certain Rare Blood Disorders (Form 8-K)	30/21/30	PU
ACCELERON PHARMA INC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	30/21/30	AQ
Moderna : Kraton, Hess rise; Apple, Moderna fall	28/21/28	AQ
ACCELERON PHARMA : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	06/21/06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Acceleron Pharma Inc.

Equities

XLRN

US00434H1086

Press Releases

Filters